June 21 The U.S. Food and Drug Administration
approved Theravance Inc's antibiotic lung drug to treat
a type of bacterial pneumonia affecting hospitalized patients,
particularly those on ventilators.
The drug, Vibativ, will reach the market in the third
quarter of 2013 for its expanded use. The drug is already
approved in the United States and Canada to treat bacterial skin
The disease, also known as nosocomial pneumonia, is a
serious lung infection as patients, particularly those on
ventilators, often cannot fight the infection.
The regulator said on Friday that Vibativ will be prescribed
only when alternative treatments are not suitable and the
expanded use is to treat only bacterial pneumonia due to
staphylococcus aureus. ()
Vibativ is already approved in Europe for the treatment of
adults with nosocomial pneumonia.
Theravance's shares were up about 2 percent at $38.25 in
The shares closed up 10 percent at $37.5 on the Nasdaq
following a Daily Mail's market report that GlaxoSmithKline
is lining up a $55 per share bid for Theravance.